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Background. Interaction between tumor cells and endothe-
lium plays a major role in cancer invasion and metastasis.
Among various cell adhesion molecules, the cognate interaction
between sialyl Lewis antigen expressed in the tumor cell surface
and E-selectin expressed on endothelial cells is considered to
be crucial for the tumor cell adhesion to the endothelium.
Methods. The sialyl Lewis X (sLX) expression in 45 speci-
mens from renal cell carcinoma patients was examined using
immunohistochemistry.
Results. In this study, we demonstrate that the immunoreac-
tivity for sLX in renal cell carcinoma specimens not only cor-
relates with conventional histopathologic parameters but also
serves as a useful indicator for the prognosis of renal cell carci-
noma.
Conclusion. Since beneficial effect of cimetidine has been re-
ported and ascribed to its inhibitory action on the expression
of E-selectin, a ligand molecule of sialyl Lewis antigen, cimeti-
dine may also show inhibitory effect on the tumor recurrence
and metastasis of renal cell carcinoma with high level of sLX
expression.
In order for tumor cells to metastasize, they first need
to interact with endothelial cells. This cell-to-cell inter-
action requires the cognate interaction of cell adhesion
molecules including E-selectin (tethering), and intercel-
lular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) (firm adhesion) that are
expressed on the endothelial cell surface. Among these
cell adhesion events the tethering step and thus the inter-
action between E-selectin and its ligand molecule sialyl
Lewis antigens is considered crucial [1]. The ligands to
E-selectin are sialyl Lewis antigens include sialyl Lewis
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X (sLX) and sialyl Lewis A (sLA). Recent reports have
indicated that the beneficial effects of cimetidine for the
patients with colorectal cancers are ascribed to its action
in inhibiting E-selectin expression on the cell surface [2,
3]. These experimental observations were confirmed by
a randomized clinical trial of cimetidine, which clearly
showed that the cimetidine treatment dramatically im-
proved the survival of colorectal cancer patients with tu-
mor cells expressing high levels of sialyl Lewis antigens
but no such effects were found when sialyl Lewis expres-
sion levels were found low or null [3].
The sialyl Lewis antigen has been used as a useful
marker for the diagnosis of various cancers in digestive
organs, pancreas, gallbladder, liver, lung, and ovary [4–
6]. The greater level of the sLX expression was found
in the metastasized lesions than the primary tumors in
cases of bladder cancer [3]. Although the incidence and
significance of expression of sLX antigen in renal cell car-
cinoma have ever been reported by only Cordon-Cardo
et al [7], cimetidine has been shown to have beneficial ef-
fects on the survival of patients with renal cell carcinoma.
In addition, Kinouchi et al [8] reported that the com-
bined therapy with interferon-a (INF-a) and cimetidine
were effective even in advanced cases of renal cell car-
cinoma. Kobayashi et al [9] found that cimetidine could
block the expression of E-selectin on the surface of hu-
man umbilical vein endothelial cells (HUVECs), which
subsequently reduced the adhesion of tumor cells to the
endothelium and prevented liver metastasis in a nude
mice model. These findings indicate that the expression
and the interaction of these cell adhesion molecules may
be a rate-determining step for the initiation of the ag-
gressive expansion of tumor cells such as invasion and
metastasis.
In this study, we demonstrate that the level of cell sur-
face expression of sLX antigen in renal cell carcinoma
tumors was correlated with the clinical outcome as well
as the histopathologic characteristics. The significance of
these findings is discussed in terms of the choice of adju-
vant cancer therapy.
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METHODS
Patients and samples
Forty-five patients who were diagnosed to have re-
nal cell carcinoma and received radical nephrectomy at
Nagoya City University Hospital between 1997 and 2002
were enrolled in this study. These patients were sub-
divided by into pT1 (14 patients), pT2 (25 patients),
pT3 (five patients), and pT4 (one patient) groups ac-
cording to the TNM classification of malignant tumors.
Metastases were present at initial diagnosis in 11 patients
(M1). No metastatic lesion was found in the other 34
patients (M0). The nuclear grading of cancer was de-
termined based on the General Rules for Clinical and
Pathological Studies on Renal Cell Carcinoma proposed
by the Fuhrman’s grading system. Histopathologic grad-
ing based on the nuclear morphology is as follows: grade
1, nuclei indistinguishable from those of normal tubular
cells; grade 2, moderately enlarged, often irregular and
slightly pleomorphic nuclei with defined nucleoli and no
bizarre forms; and grade 3, numerous bizarre or giant nu-
clei. The classification of vascular invasion is as follows:
pV0, no vascular invasion in specimen; pV1a, microscopic
vascular invasion in a renal vein; pV1b, macroscopic vas-
cular invasion in a renal vein; pV2, vascular invasion in
vena cava. For the detection of distant metastasis, all the
patients were checked at least twice per year for occur-
rence of metastasis by x-ray studies, computed tomog-
raphy (CT), and bone scintigraphy during the follow-up
period.
Immunohistochemistry
Paraffin-embedded tissue sections obtained from 45
patients during the operation were deparaffinized in a
cleaning solution (Histochoice) (Amresco, Solon, OH,
USA), rehydrated in a graded series of ethanol (100%,
95%, 70%, and 50%), and washed in distilled water.
Endogenous peroxidase activity was quenched by 1.5%
H2O2 in phosphate-buffered saline (PBS) for 15 minutes
followed by washing twice with PBS. Nonspecific pro-
tein recognition by the antibody was blocked in casein
wash buffer (containing 0.3% casein and 0.5% Tween-20
in PBS) for 30 minutes. Tissue sections were then incu-
bated for 1 hour at room temperature with the primary
antibody, monoclonal anti-sLX antibody (Seikagaku Co.,
Tokyo, Japan), or anti-E-selectin antibody (Dako, Copen-
hagen, Denmark). After being washed twice in 1:10
casein wash buffer for 5 minutes, and incubated with
1:250 biotinylated antimouse IgG (Vector Laboratories,
Burlingame, CA, USA) for 30 minutes, the specific in-
tracellular immunoreactivity was detected by incubation
with avidin-biotin/horseradish peroxidase complex (Vec-
tor Laboratories) for 45 minutes at room temperature fol-
lowed by color development in 0.05% diaminobenzidine
(DAB)/0.01% H2O2/PBS (pH 7.6) chromogen (Sigma
Chemical Co., St. Louis, MO, USA) for 5 minutes. Color
development was stopped by washing in distilled water,
and sections were lightly counterstained in hematoxylin,
dehydrated in a graded series of alcohol, cleared in xy-
lene, and finally mounted in Eukitt.
Semiquantitative analysis of sLX expression
The degree of sLX expression was estimated and clas-
sified into one of five grades as described previously [10].
Immunoreactivity of sLX was classified into a scale of 0
to 4 on the basis of staining of tumor cells as follows: 0,
no staining; 1, focal, weak staining; 2, strong staining of
<25% of cells or moderate staining of <80%; 3, strong
staining of 25% to 50% or moderate staining of >80%;
and 4, strong staining of >50%. The immunostained tis-
sue section slides were examined and scored indepen-
dently by two of the authors blinded to any other patho-
logic or clinical information. In 60% of cases the decisions
were consistent, and the other 40% were reviewed until
agreement was achieved.
Statistical analysis
Data are presented as the mean ± standard error of
the mean (SEM). Individual groups (each pathologic
grade and TNM classification) were then compared us-
ing the nonparametric Mann-Whitney U test, general-
ized Wilcoxon test and Student t test. For all analyses a
probability value of P < 0.05 was considered statistically
significant.
RESULTS
Among the 45 renal cell carcinoma patients enrolled in
this study, 27 (60%) had grade 1 tumors, 11 (24.4%) had
grade 2 tumors, and seven (15.6%) had grade 3 tumors.
All the tumor tissues were examined for the expression of
sLX and compared with histopathologic findings and clin-
ical characteristics, including the recurrence rate and the
incidence of metastasis. The staining of sLX antigen was
predominantly detected in the cell membrane of tumor
cells or intercellular matrix. In most cases, heterogeneity
of sLX staining was noted within individual tumor sam-
ples showing either variation in the intensity of staining
or patchiness of the DAB staining (Fig. 1).
In Figure 2A, the positive correlation of semiquantita-
tive evaluation of the sLX expression (immunoreactivity)
and the tumor staging (pT) are demonstrated. There were
significant differences in sLX expression between pT1a
and pT3 (P = 0.009 by Mann-Whitney test), and pT2
and pT3 (P = 0.034). Although only single cases were
assigned to pT1b and pT4, there was a strong positive
correlation between the size of tumor mass and its exten-
sion and the extent of sLX antigen expression. Interest-
ingly, the level of sLX expression was positively correlated
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Fig. 1. Histopathologic findings of the tissue expression of sialyl Lewis X (sLX) in renal cell carcinoma. sLX staining of three representative renal
cell carcinoma cases are presented. (A, C, and E) Immunostaining of sLX antigen. (B, D, and F) Hematoxylin and eosin staining of renal cell
carcinoma. The tissue sections of the same patients (A and B; C and D; and E and F) were stained. The level of sLX expression is expressed as the
immunoreactivity (IR) to the mouse monoclonal antibody to human sLX antigen (see the Methods section for the details). The pathologic diagnosis,
based on the General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma proposed by the Japanese Urological and Pathological
Association [11], of each patient is also indicated. Abbreviations are: G, nuclear morphology; pT, tumor size; pV, vascular infiltration.
with the rate of local recurrence and metastasis of cancer
(collectively called “recurrence” in this study) (Fig. 2B).
Among 34 patients, the tumor recurrence within 3 years
after the radical nephrectomy was noted in 11 cases
(32%). In these patients, the level of sLX expression of
the original tumors that were resected was significantly
higher than those without recurrence.
We then looked at the extent of vascular infiltration of
the original tumor tissue. Whereas no vascular infiltration
of tumor cells was noted in 23 out of 24 patients without
recurrence, significant vascular infiltration was evident in
all the patients with tumor recurrence (11 patients). Only
one patient had a sign of mild local vascular infiltration
but no recurrence was detected. These findings of vas-
cular infiltration with regard to the level of sLX expres-
sion (immunoreactivity) are depicted in Figure 2C. These
observations clearly illustrates that the tumor with high
expression of sLX antigen had a higher level of vascular
infiltration (P < 0.001, overall). The patients with the tu-
mor with high expression of sLX antigen showed a signif-
icantly higher rate of tumor recurrence (P < 0.05). There
was no significant difference between the expression of
sLX and pathologic subtypes of renal cell carcinoma.
Among 45 cases, studied 36 (80%) and nine (20%)
cases were pathologically diagnosed as the clear cell type
and the chromophobe cell type, respectively. However,
there was no statistical significance in the level of sLX
expression with regard to the cell types. No statistical
significance was found between the tumor cell type and
the rate of tumor occurrence. In either cell types, the tu-
mor of low sLX immunoreactivity showed less probability
of local recurrence. Moreover, the level of sLX expres-
sion in patients with distant metastasis was significantly
higher than that without distant metastasis (P < 0.0001).
Thus, the expression levels of sLX antigen appear to be
a significant predictor for the development of metastases
and tumor-free survival rate. In Figure 2D, we examined
the relationship between the pathologic grading based on
the nuclear morphology and the level of sLX expression.
Whereas most of the cases (27 patients) were classified
into grade 1, tumors from 11 and seven patients were
classified into grades 2 and 3, respectively. Interestingly,
there was a strong difference in the levels of cell surface
sLX expression and this pathologic classification. Lower
grade tumor showed significantly lower levels of sLX ex-
pression: between grades 1 and 2 (P = 0.04 by Mann-
Whitney test); between grades 1 and 3 (P = 0.0002 by
Mann-Whitney test); and no statistical significance be-
tween grades 2 and 3.
Finally, we have examined the metastasis-free period
by the classification based on the level of sLX expres-
sion. As shown in Figure 3, we found a significant differ-
ence in the rate of tumor-free survival between cases with
immunoreactivity ≤2 (low sLX expression) and those
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Fig. 2. Positive correlation of the level of sialyl Lewis X (sLX) antigen expression and the tumor staging (pT), the cancer recurrence, the degree of
vascular infiltration of tumor, and the nuclear grading of tumor cells. (A) sLX expression of tumor tissues and T stages. The level of sLX expression
is determined according to the results of immunostaining of each tumor tissue and expressed as immunoreactivity (IR) score. The tumor tissues are
classified according to the tumor staging (pT) based on the size of primary tumor. The average sLX expression levels were compared among these
groups and the differences were assessed by Mann-Whitney test. N is the number of renal cell carcinoma cases in each category. (B) sLX expression
and the cancer recurrence. The average sLX expression levels were compared between groups with and without cancer recurrence (local recurrence
and detection of distant metastasis). The statistical differences were found between these two groups (P < 0.05). (C) Vascular infiltration of tumor
cells and sLX expression. The extents of vascular invasion of tumor cells were determined by microscopic examination of the resected pathologic
specimen obtained during surgical operation. Note that significant statistical differences (P < 0.05) were found between pV0 and pV1a, and pV0
and pV2. No significant differences were found between pV1a and pV2. (D) Positive correlation between the pathologic grading and the level of
sLX expression. The pathologic grading was determined for each case based on the nuclear morphology of tumor cells [11]. Significant differences
in the level of sLX expression were found between pathologic grades 1 and 3 (P < 0.001) and grades 1 and 2 (P < 0.05).
with immunoreactivity >2 (high sLX expression) (P =
0.0047 by generalized Wilcoxon test). The cumulative 3-
year tumor-free survival rate of the immunoreactivity ≤2
group of renal cell carcinoma patients (N = 16) was 90%,
whereas that of the immunoreactivity >2 group (N =
11) was only 38.5%. Any greater differences were found
when we classified the renal cell carcinoma cases by tu-
mor grading, tumor cell types, or pT staging (data not
shown).
DISCUSSION
Currently, urologic surgeons do not have powerful
measures to assess the aggressiveness of advanced renal
cell carcinoma and predict future prognosis of the pa-
tients besides pathologic diagnosis. Neither do we have
any better adjuvant therapeutic options to construct ef-
fective therapeutic strategies according to the individ-
ual characteristics of tumor other than radical nephrec-
tomy. In this study, we demonstrate that expression of sLX
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Fig. 3. The level of sialyl Lewis X (sLX) expression and the metastasis-
free period. All the renal cell carcinoma cases were classified into two
groups: low sLX expression [immunoreactivity (IR) ≤2] and high sLX
expression (IR >2). Twenty-seven cases without metastasis upon the
initial diagnosis were followed up for 3 years. All patients received med-
ical check-ups, including x-ray studies, computed tomography (CT), and
whole body bone schintigraphy at least twice a year during the follow-up
period. The level of sLX expression was assessed by immunohistochem-
istry using the resected tumor tissue upon radical nephrectomy (year =
0). Statistically significant difference in the metastasis-free period was
observed between low sLX expression (IR ≤2) and high sLX expression
(IR >2) (P = 0.0047).
antigen on renal cell carcinoma tumor cells showed strong
positive correlation with both macroscopic and micro-
scopic pathologic findings, and clinical outcomes such as
metastasis and tumor-free survival.
The major benefit of these findings in terms of a pro-
posal of novel therapy comes from previous reports with
colorectal cancers and the dramatic beneficial effect of
cimetidine [2, 9, 11, 12]. For example, Matsumoto et al [2,
12] reported that the treatment with cimetidine markedly
reduced the frequency of metastasis and significantly in-
creased the survival rate in the patients whose tumor cells
expressed higher levels of the sLX and the sLA epitopes.
However, cimetidine was not effective in the patients
with lower levels (or none) of these epitopes, although
such cancers are considered to be less aggressive. It was
demonstrated that a 1-year course of cimetidine pro-
duced a 10-year survival rate of 96% in patients whose tu-
mor had high sLX expression with cimetidine, compared
to only 35% in control cases without cimetidine treatment
[11]. Similar observations with cimetidine were reported
with renal cell carcinoma [8].
Although the mechanism of cimetidine to endow can-
cer patients of high sLX antigen expression in tumors
with the beneficial effects, Kobayashi et al [9] clearly
showed that this effect of cimetidine is ascribed to the
down-regulation of E-selectin, a ligand molecule for sia-
lyl Lewis antigens, that is expressed on the endothelium.
They demonstrated that cimetidine could block the ex-
pression of E-selectin and thus inhibited the adhesion
of tumor cells to the HUVECs and that the cimetidine
administration in nude mouse model also inhibited the
transsplenic liver metastasis [9]. Other possible effects of
cimetidine include (1) inhibition of the activity of sup-
pressor T lymphocytes bearing a histamine type 2 recep-
tor in cancer patients [11, 13]; (2) cimetidine, acting as an
antioxidant, inhibits tumor growth [14]; (3) prevention of
postoperative alterations of lymphocyte subpopulations
[15]; and (4) maintenance of natural killer cell activity
[16].
Metastasis is the hallmark of malignant phenotype of
cancer. The involvement of either sLA or sLX in adhesion
to the endothelium is still controversial and may depend
on the tissue types of cancers [17, 18]. The hematoge-
nous metastasis of colorectal cancer and pancreatic can-
cer is mainly mediated by sLA/E-selectin interaction [18]
whereas that of renal cell carcinoma involves primarily
sLX in at least three renal cell carcinoma cell lines in
cell culture experiments [19]. Furthermore, Steinbach et
al [19] concluded that cytokines significantly affect the
adhesion of renal cell carcinoma to the endothelium,
and that cytokine-induced increases in tumor endothelial
binding are mediated at least in part by the E-selectin:sLX
interaction.
In one of our previous studies [1], we reported that
adhesion of tumor cell line QG90 derived from lung can-
cer to HUVEC was dependent on E-selectin expression
on the cell surface of HUVEC. The adhesion of cancer
cell to HUVEC and E-selectin expression was induced
by interleukin (IL)-1b . The various inhibitors of the nu-
clear factor-kappaB (NF-jB) activation cascade could
block the cell adhesion mediated by E-selectin and sLX
as E-selectin gene expression is under the transcriptional
control of NF-jB. However, the action of cimetidine in
blocking E-selectin does not appear to be at the level of
transcription but rather at a step after transcription [9].
In this regard, it may be worth nothing that a possible
involvement of other regulatory molecules such as p38
mitogen-activated protein kinase (MAPK), in addition
to NF-jB, also participating in the IL-1b signaling [20,
21] should be examined as p38 MAPK is required for
the E-selectin expression most likely at the level of post-
transcription [20–25]. In this context, the issue of whether
cimetidine but not other histamine receptor (H2R) antag-
onists could interfere with such signaling cascade should
also be explored.
The design of our study took into account the similar-
ity between renal cell carcinoma and colorectal cancer in
that cimetidine has beneficial effects on both cancers. As
shown in this study, the immunoreactivity to sLX on renal
cell carcinoma specimens was remarkably correlated with
T stage and tumor-free survival (Figs. 2 and 3). Semiquan-
titative analysis revealed that elevated expression of the
sLX epitope was associated with the potential for metas-
tasis, suggesting the importance of this epitope as a ligand
for E-selectin. If the cimetidine given to the patients can
efficiently block the expression of E-selectin on vascu-
lar endothelial cells, even malignant renal cell carcinoma
cells expressing higher levels of sLX would not be able to
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adhere to the endothelium and the frequency of metas-
tasis in the patients would be reduced, resulting in the
beneficial effects for the patient survival. Taken together,
these results suggested a beneficial effect of cimetidine
on renal cell carcinoma patients, presumably by block-
ing the expression of E-selectin on vascular endothelial
cells and inhibiting the adhesion of cancer cells. Future
studies should clarify the effect of cimetidine on renal cell
carcinoma with a high level of sLX expression.
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